Supriya Lifescience Limited, a global leader in the manufacturing of active pharmaceutical ingredients (APIs), announces a significant milestone in its global operations with the successful attainment of the Good Manufacturing Practice (GMP) certification from Brazil’s Regulatory Authority, ANVISA, for its manufacturing facility located in Lote Parshuram, Ratnagiri District, Maharashtra, India.
The recent clearance obtained from this comprehensive audit showcases Supriya’s commitment to excellence but also signifies the successful registration of 8 APIs with CADIFA. This milestone is poised to expedite and streamline the registration process for the company’s remaining APIs, facilitating a smoother pathway for their introduction into the Brazilian market.
Under the astute leadership of chairman and managing director, Dr. Satish Wagh, Supriya Lifescience Limited's Lote Factory underwent a rigorous inspection by ANVISA, emerging with an exemplary record of "Zero" Observations in compliance. This accomplishment underscores the company's unwavering commitment to upholding the highest quality standards and employing advanced production and manufacturing techniques.
Dr. Satish Wagh, chairman and managing director, Supriya Lifescience stated, “It is a privilege for us to have obtained the GMP accreditation from ANVISA, which clearly demonstrates our strength of manufacturing capabilities from the state-of-the-art world class facility at Lote Parshuram, Ratnagiri District, in Maharashtra. This achievement truly speaks to our team's unwavering determination in adhering to rigorous standards for quality assurance, production processes, and overall adherence. Moreover, this certification not only enhances our presence in the Brazilian market but also strengthens our reputation as a trustworthy and quality-oriented pharmaceutical company and will increase our presence in the South American market.”
The success of Supriya Lifescience in achieving Brazil's strict GMP standards positions the company for significant growth and has a potential of approximately Rs. 200 crore in the Brazilian market. The approval by ANVISA, demonstrates Supriya's persistent commitment to pharmaceutical quality control, data integrity, and GMP compliance in its manufacturing operations.
Established in the year 1987, Supriya Lifescience is a global leading manufacturer of active pharmaceutical ingredients. Its state-of-the-art facility is certified by the US FDA, EDQM, EUGMP, NMPA & Health Canada. The facility is located in Khed, District Ratnagiri and is headquartered in Mumbai, India.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!